Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …

Background In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated versus
19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis
characterized by asthma, systemic manifestations, and blood and tissue eosinophilia …

Objective To describe the efficacy and safety of biologics for the treatment of eosinophilic
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …

Background Eosinophilic granulomatosis with polyangiitis (EGPA), a rare vasculitis with
substantial morbidity, is characterized by asthma, eosinophilia, sinusitis, pulmonary …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis associated
with significant morbidity and mortality that has historically been treated with systemic …

Objective To describe the efficacy and safety of omalizumab, an anti‐IgE monoclonal
antibody, in patients with refractory and/or relapsing eosinophilic granulomatosis with …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …

Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of
antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct …